Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 372

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 372
---
etic counseling for patients, technical support for the Personalized Genetic Medicine (PGM) department, genetic -commercialsupport for distributors, and the provision of test result communication to clients and distributors. Services are rendered remotely, with on -sitevisits agreed upon in advance based on the budget provided. Additionally, Heritas Argentina may provide work tools such as a notebook, email account, or other necessary resources, which are subject to proper use; misuse could result in a breach of contract. The original contract was signed on June1, 2023, with a term of one year and was later amended to extend its term through April1, 2025, with the possibility of renewal by mutual written agreement. Either party may terminate the contract early with 30 days’ notice, without penalty. The current term of the agreement is for ten months from the acceptance date, with renewal contingent on mutual written agreement. The professional operates independently, may provide services to other clients, and must maintain professional secrecy and confidentiality. Invoices are submitted through the fifth calendar day of each month, with payment made via bank transfer on the first Thursday of the following month. Monthly compensation is made in Argentine Pesos, subject to automatic adjustments aligned with healthcare sector wage agreements ratified by relevant authorities. Reproductive Genetics: Non-Invasive Prenatal Testing (“NIPT”) We have developed a proprietary non -invasiveprenatal screening test which incorporates a proprietary developed bioinformatics pipeline to analyze fetal DNA from maternal blood samples. The test, which can be administered from nine weeks of pregnancy through birth, screens for common genetic alterations including Down, Edwards, and Patau syndromes, sex chromosome abnormalities, specific aneuploidies, and pathogenic microdeletions/microduplications that could result in a range of genetic disorders. Our NIPT also determines the sex of the fetus and is recommended for all pregnant women, regardless of age and/or risk. Oncology: Hereditary Cancer Test This genetic test is designed to detect inherited mutations linked to an increased risk of hereditary cancers, including breast, ovarian, pancreatic, gastric, uterine, prostate, and renal cancers. Utilizing a blood sample, the test evaluates 113 genes for germline mutations, somatic point mutations (“SNV”), indels, and copy number variants (“CNV”), providing insights that are able to confirm clinical diagnoses, forecast disease progression, guide early symptom detection, inform family planning, genetic counseling, and facilitate clinical trial enrollment. This test is intended